Log In
Print this Print this

fenofibrate/simvastatin (Cholib)

  Manage Alerts
Collapse Summary General Information
Company Abbott Laboratories
DescriptionFixed-dose combination of 145 mg fenofibrate and either 20 or 40 mg simvastatin
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDyslipidemia
Indication DetailsAdjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidemia to reduce triglycerides and increase HDL-C levels when LDL-C levels are adequately controlled with the corresponding dose of simvastatin monotherapy
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today